Medtronic to Invest up to $90M in Anteris Technologies

Anteris Technologies announced that Medtronic will make a strategic investment of up to $90 million in the transcatheter heart valve (THV) maker.

The private placement requires Medtronic to purchase a 16-19.99% stake in Anteris. Further, Anteris proposed a $200 million underwritten public offering with a 30-day option to buy an additional $30 million shares of common stock at the public offering price.

Anteris was founded in Australia and holds a significant presence in Minneapolis, Minn. The company’s DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow.

The valve is made using one piece of molded ADAPT tissue, the company’s patented anti-calcification tissue technology. ADAPT tissue is FDA cleared, has been used clinically for over a decade, and distributed for use in over 55,000 patients across the globe. The DurAVR THV system is comprised of the DurAVR valve, the ADAPT tissue, and the balloon-expandable ComASUR delivery system.

The system is being evaluated in the company’s PARADIGM trial, with the first patients enrolled and implanted with the DurAVR THV in Denmark during Q4 2025.

Anteris said it plans to use the proceeds from the offering and private placement to support ongoing recruitment and study execution of the PARADIGM trial, as well as manufacturing capabilities. A part of the proceeds will also fund ongoing R&D for v2vmedtech, with balance allocated to working capital and other general corporate purposes.